The statement open to discussion on endpoints that could support a potential Accelerated Approval application and verify clinical benefitpresenting earlier market entry bodes well. I read that to be an industry standard benchmark that was not previously established. Might dosage adjustments be the catalyst to this? I'm not sure, but further updates will no doubt follow.
DXB Price at posting:
45.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)